EarningsQ2 2026 Earnings Report
DE:LDE Q2 2026 EPS Results
Actual EPS-€0.17
Consensus EPS-€0.20
Beat/MissBeat by +€0.03
One Year Ago EPS-€0.05
DE:LDE Q2 2026 Revenue Results
Actual Revenue€30.45M
Expected Revenue€28.54M
Beat/MissBeat by +€1.92M
YoY Revenue Growth+4.92%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
DE:LDE Upcoming Earnings
Lifecore Biomedical's next earnings date is estimated for May 12, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:LDE Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.Company Guidance
Guidance Reaffirmed for 2026
Company reaffirmed 2026 revenue guidance of $120.0M–$125.0M and adjusted EBITDA guidance of $20.5M–$25.0M, and reiterated expectation to deliver full-year guidance despite H1 timing headwinds.
Committed Customer Demand Inflection (2027–2028)
Largest customer's contractually committed fill/finish demand is expected to double beginning in 2027, with committed demand increasing by more than 200% in 2028 versus 2026, creating a clear multi-year volume inflection.
Strong New Business Momentum
Added 6 new programs in Q2 (including 3 in June), 9 year-to-date wins through June 30 and 13 wins over the last 12 months; 2 of the Q2 programs expected to generate commercial revenue in 2028–2029; >60% of competed opportunities since mid-last year were late-stage or commercial site transfers (lower market risk).
Late-Stage Pipeline and Commercialization Progress
Management highlights 11 existing development programs with potential to commercialize by year-end 2028 and successful completion of multiple PPQ batches for a customer targeting commercialization in 2027 (PPQ is an important pre-commercial milestone).
Regulatory & Quality Successes
Hosted 7 audits/inspections in Q2 (5 customer audits, 2 regulatory), completed all with no material issues; successful PMDA inspection opens pathway to the Japanese market for HA and aseptic fill/finish products.
SG&A and Cost Reduction Momentum
Fifth consecutive quarter of period-over-period declines in SG&A and R&D; cumulative reductions of $16.2M since late 2024; Q2 SG&A down 11.2% YoY to $8.0M and management expects run-rate SG&A (ex-one-offs) to be ~ $6M/quarter in back half of 2026.
Improved Liquidity & Cash Discipline
Ended Q2 with approximately $38.8M of liquidity (cash $17.2M and $21.6M revolver availability); management began paying portion of debt service in cash (vs PIK) and projects 2026 free cash flow of ~$7M–$10M.
Capacity Positioning and Operational Readiness
Management expects to utilize ~60% of installed capacity by 2029 and believes current capacity plus incremental direct labor can support midterm growth; evaluating Site 3 and other options as needed.
DE:LDE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed